Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-02-23 Annual Report
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Annual Report for the year ended 31 December 2021 114 pages 15.6MB
Annual Report Classification · 100% confidence The document is titled 'Telix Pharmaceuticals Limited 2021 Annual Report' and contains detailed sections typical of an annual report, including a letter from the chairman, business overview, technology description, milestones, ESG report, directors' report, and financial report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content covers comprehensive company information, financial performance, and strategic outlook for the fiscal year 2021. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-02-23 English
2021 Full Year Results Presentation 33 pages 3.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals Limited, containing extensive information about the company's strategic priorities, pipeline, commercial launch updates, clinical programs, financial highlights, and market positioning. It includes forward-looking statements, regulatory approvals, product launch timelines, and detailed descriptions of clinical trials and therapeutic programs. The content is structured as a comprehensive overview aimed at investors or stakeholders, focusing on financials, strategy, and market position rather than being a formal regulatory filing or standalone financial report. The length (15,000 characters) and depth of content indicate it is not a brief announcement or a simple report publication notice. The presence of slides, disclaimers, and forward-looking statements is typical of an investor presentation. Therefore, the document best fits the category of an Investor Presentation (IP).
2022-02-23 English
Commercial Distribution Agreement for Illuccix for Australia 2 pages 256.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing a commercial distribution agreement for a pharmaceutical product (Illuccix) in Australia. It contains no financial statements, no detailed financial performance data, no management discussion of financial results, no voting results, no legal proceedings, no executive compensation details, and no regulatory certifications. It is a corporate announcement about a business agreement and market expansion. The document length is 6568 characters, which is sufficient for a detailed announcement but does not constitute a full financial or annual report. The content fits best under a general regulatory announcement category rather than a specific financial report or meeting material. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-02-15 English
Ceasing to be a substantial holder 2 pages 182.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001 Section 671B, titled 'Notice of Ceasing to be a Substantial Holder'. It details changes in relevant interests of a substantial shareholder (FIL Limited) in Telix Pharmaceuticals Limited, including dates, number of shares sold, resulting interest, and associations. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document length is 4101 characters, and it contains detailed shareholding changes, not just an announcement or certification. Therefore, it is classified as MRQ with high confidence.
2022-02-13 English
Share Purchase Plan extended to Friday 25 February 2022 2 pages 203.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited announcing the extension of the closing date for a Share Purchase Plan (SPP). It details the terms, timetable, and purpose of the SPP, which is a fundraising activity involving the issuance of new shares to shareholders. There is no financial report, earnings data, or management discussion present. The content focuses on capital raising and share issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not merely an announcement of a report but a substantive update on financing activity.
2022-02-08 English
Update - Proposed issue of securities - TLX 10 pages 38.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a securities purchase plan and a placement by Telix Pharmaceuticals Limited. It includes specifics such as offer price, number of securities, timetable, fees, and conditions related to the issuance of new shares. The content focuses on the company's capital raising activities through issuing new shares and does not contain financial statements or earnings data. It is an announcement related to fundraising and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information, confirming it is not a brief announcement or a report publication notice.
2022-02-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.